BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36922934)

  • 1. The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand-dependent Cancer Models.
    Phillips C; Bhamra I; Eagle C; Flanagan E; Armer R; Jones CD; Bingham M; Calcraft P; Edmenson Cook A; Thompson B; Woodcock SA
    Cancer Res Commun; 2022 Sep; 2(9):914-928. PubMed ID: 36922934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Porcupine inhibitors: Novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway.
    Shah K; Panchal S; Patel B
    Pharmacol Res; 2021 May; 167():105532. PubMed ID: 33677106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma.
    Jiang X; Hao HX; Growney JD; Woolfenden S; Bottiglio C; Ng N; Lu B; Hsieh MH; Bagdasarian L; Meyer R; Smith TR; Avello M; Charlat O; Xie Y; Porter JA; Pan S; Liu J; McLaughlin ME; Cong F
    Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12649-54. PubMed ID: 23847203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition.
    Flanagan DJ; Woodcock SA; Phillips C; Eagle C; Sansom OJ
    Pharmacol Ther; 2022 Oct; 238():108179. PubMed ID: 35358569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand-Addicted Pancreatic Cancer.
    Aguilera KY; Le T; Riahi R; Lay AR; Hinz S; Saadat EA; Vashisht AA; Wohlschlegel J; Donahue TR; Radu CG; Dawson DW
    Mol Cancer Ther; 2022 Jun; 21(6):936-947. PubMed ID: 35313331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions.
    Picco G; Petti C; Centonze A; Torchiaro E; Crisafulli G; Novara L; Acquaviva A; Bardelli A; Medico E
    EMBO Mol Med; 2017 Mar; 9(3):293-303. PubMed ID: 28100566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
    Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel PORCN inhibitor WHN-88 targets Wnt/β-catenin pathway and prevents the growth of Wnt-driven cancers.
    Yang Q; Qin T; An T; Wu H; Xu G; Xiang J; Lei K; Zhang S; Xia J; Su G; Wang D; Xue M; Kong L; Zhang W; Wu S; Li Y
    Eur J Pharmacol; 2023 Apr; 945():175628. PubMed ID: 36858339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/β-catenin signaling in CD133
    Klose J; Eissele J; Volz C; Schmitt S; Ritter A; Ying S; Schmidt T; Heger U; Schneider M; Ulrich A
    BMC Cancer; 2016 Nov; 16(1):896. PubMed ID: 27855654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.
    Liu J; Pan S; Hsieh MH; Ng N; Sun F; Wang T; Kasibhatla S; Schuller AG; Li AG; Cheng D; Li J; Tompkins C; Pferdekamper A; Steffy A; Cheng J; Kowal C; Phung V; Guo G; Wang Y; Graham MP; Flynn S; Brenner JC; Li C; Villarroel MC; Schultz PG; Wu X; McNamara P; Sellers WR; Petruzzelli L; Boral AL; Seidel HM; McLaughlin ME; Che J; Carey TE; Vanasse G; Harris JL
    Proc Natl Acad Sci U S A; 2013 Dec; 110(50):20224-9. PubMed ID: 24277854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Functional Landscape of Patient-Derived RNF43 Mutations Predicts Sensitivity to Wnt Inhibition.
    Yu J; Yusoff PAM; Woutersen DTJ; Goh P; Harmston N; Smits R; Epstein DM; Virshup DM; Madan B
    Cancer Res; 2020 Dec; 80(24):5619-5632. PubMed ID: 33067269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of RNF43 frameshift mutations that drive Wnt ligand- and R-spondin-dependent colon cancer.
    Yamamoto D; Oshima H; Wang D; Takeda H; Kita K; Lei X; Nakayama M; Murakami K; Ohama T; Takemura H; Toyota M; Suzuki H; Inaki N; Oshima M
    J Pathol; 2022 May; 257(1):39-52. PubMed ID: 35040131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells.
    Li Y; Oliver PG; Lu W; Pathak V; Sridharan S; Augelli-Szafran CE; Buchsbaum DJ; Suto MJ
    Cancer Lett; 2017 Mar; 389():41-48. PubMed ID: 28043913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).
    Katoh M
    Int J Oncol; 2017 Nov; 51(5):1357-1369. PubMed ID: 29048660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma.
    Arensman MD; Kovochich AN; Kulikauskas RM; Lay AR; Yang PT; Li X; Donahue T; Major MB; Moon RT; Chien AJ; Dawson DW
    Oncogene; 2014 Feb; 33(7):899-908. PubMed ID: 23416978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers.
    Zhong Z; Sepramaniam S; Chew XH; Wood K; Lee MA; Madan B; Virshup DM
    Oncogene; 2019 Oct; 38(40):6662-6677. PubMed ID: 31391551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
    Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
    Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.
    Steinhart Z; Pavlovic Z; Chandrashekhar M; Hart T; Wang X; Zhang X; Robitaille M; Brown KR; Jaksani S; Overmeer R; Boj SF; Adams J; Pan J; Clevers H; Sidhu S; Moffat J; Angers S
    Nat Med; 2017 Jan; 23(1):60-68. PubMed ID: 27869803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations.
    Fischer MM; Yeung VP; Cattaruzza F; Hussein R; Yen WC; Murriel C; Evans JW; O'Young G; Brunner AL; Wang M; Cain J; Cancilla B; Kapoun A; Hoey T
    Sci Rep; 2017 Nov; 7(1):15270. PubMed ID: 29127379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth.
    Wang Q; Zhou Y; Rychahou P; Harris JW; Zaytseva YY; Liu J; Wang C; Weiss HL; Liu C; Lee EY; Evers BM
    Cancer Res; 2018 Jun; 78(12):3163-3175. PubMed ID: 29666061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.